Maria Zannes - President & CEO, Director at bioAffinity Technologies, Inc.

Insider Transactions and Holdings

Class	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Common Stock	280K	$645K	$2.65	Jan 10, 2025	Direct
Stock Option (right to buy)	0			Apr 8, 2024	Direct	Common Stock

Showing 1 to 2 of 2 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.